Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Sofinnova Partners

Investor type Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 282
Average round size
info
The average size of a deal this fund participated in
$23M
Portfolio companies 163
Rounds per year 5.64
Lead investments 91
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.42
Exits 58
Key employees 11
Stages of investment
Early Stage Venture
Late Stage Venture
Seed

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Pharmaceutical
  • Therapeutics
Summary

Sofinnova Partners appeared to be the VC, which was created in 1972. The company was established in Europe in France. The leading representative office of defined VC is situated in the Paris.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - France. We can highlight the next thriving fund investment areas, such as Health Care, Medical Device. Among the most popular portfolio startups of the fund, we may highlight Addex Therapeutics, DBV Technologies, MedDay. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. The fund has no exact preference in a number of founders of portfolio startups. When startup sums 4 of the founder, the probability for it to get the investment is little.

Besides them, we counted 11 critical employees of this fund in our database.

The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the Sofinnova Partners, startups are often financed by Gimv, Idinvest Partners, Bpifrance. The meaningful sponsors for the fund in investment in the same round are Seventure Partners, Idinvest Partners, Auriga Partners. In the next rounds fund is usually obtained by Gimv, Andera Partners, Venrock.

This Sofinnova Partners works on 5 percentage points less the average amount of lead investments comparing to the other organizations. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. The top amount of exits for fund were in 2010. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is generally included in 7-12 deals every year. The average startup value when the investment from Sofinnova Partners is 10-50 millions dollars. The real fund results show that this VC is 18 percentage points more often commits exit comparing to other companies.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Sofinnova Partners:
Typical Co-investors
Sofinnova Partners is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Sofinnova Partners:

Funds with similar focus

Funds from France
Funds with similar focus located in France:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Mablink Bioscience

Biotechnology
Pharmaceutical
$36M14 Oct 2022 Lyon, Rhone-Alpes, France

Abivax

Biotechnology
$58M02 Sep 2022 Paris, Ile-de-France, France

F2G

Biotechnology
Genetics
Health Care
Medical
Pharmaceutical
$70M04 Aug 2022 Manchester, England, United Kingdom

Rgenix

Biotechnology
Health Care
Pharmaceutical
$55M11 Jul 2022 New York, New York, United States

Biosyntia

Biopharma
Biotechnology
Clinical Trials
Manufacturing
Medical Device
$13M06 Jul 2022 Denmark, Capital Region of Denmark, Denmark

Micropep Technologies

Agriculture
Biotechnology
Chemical
Lead Generation
$10M27 Jun 2022 France, Auvergne-Rhône-Alpes, France

Moon Surgical

Health Care
Medical Device
$31M07 Jun 2022 Paris, Ile-de-France, France

GFBiochemicals

Biotechnology
Life Science
$17M05 May 2022 Milan, Lombardy, Italy

Prometheus Materials

Advanced Materials
Green Building
Sustainability
$8M12 Apr 2022 Boulder, Colorado, United States
News
Founded last year, Mozart Therapeutics lands $55M to develop therapies for celiac and other diseases

– Mozart Therapeutics, a Seattle-based biotech startup, raised $55m funding.
– The round was led by ARCH Venture Partners along with Sofinnova Partners.
– Other backers include MRL Ventures Fund from Merck, Leaps by Bayer, and Eli Lilly & Company.

Tissium Raises €50M in Series C Financing

– Tissium is a medtech company developing biomorphic programmable polymers for tissue reconstruction.
– Company raised €50M in Series C financing.
– The round was led by Cathay Health, affiliated to global investment firm Cathay Capital, with participation from existing shareholders Sofinnova Partners, and others.
– The company intends to use the funds to continue to execute on its development plan, up to the commercialization of its nerve repair, hernia repair and cardiovascular sealant products.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Sofinnova Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: